ResMed Inc.
RMDResMed Inc. is a healthcare company that specializes in developing, manufacturing, and marketing medical equipment primarily for the treatment of sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Founded in 1989, the company is known for its innovative sleep and respiratory care solutions, including devices such as CPAP machines, ventilators, and related accessories. ResMed operates globally, serving both individual patients and healthcare providers.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 18, 2025 | $0.60 | 2025-11-13 | 2025-11-13 |
| September 18, 2025 | $0.60 | 2025-08-14 | 2025-08-14 |
| June 12, 2025 | $0.53 | 2025-05-08 | 2025-05-08 |
| March 20, 2025 | $0.53 | 2025-02-13 | 2025-02-13 |
| December 12, 2024 | $0.53 | 2024-11-07 | 2024-11-07 |
Dividends Summary
- Consistent Payer: ResMed Inc. has rewarded shareholders with 54 dividend payments over the past 13 years.
- Total Returned Value: Investors who held RMD shares during this period received a total of $20.00 per share in dividend income.
- Latest Payout: The most recent dividend of $0.60/share was paid 36 days ago, on December 18, 2025.
- Yield & Schedule: RMD currently pays dividends quarterly with an annual yield of 0.89%.
- Dividend Growth: Since 2012, the dividend payout has grown by 252.9%, from $0.17 to $0.60.
- Dividend Reliability: RMD has maintained or increased its dividend for 54 consecutive payments.
Company News
The global sleep apnea devices market is projected to grow from USD 9.5 billion in 2024 to USD 15.8 billion by 2032, with a CAGR of approximately 6%. Growth is driven by rising OSA prevalence, technological advancements, increased awareness, and expanding healthcare infrastructure. North America leads the market with over 45% share, while Asia-Pa...
BVI announced the appointment of Jim Hollingshead as President & CEO, succeeding Shervin Korangy. Hollingshead brings over 20 years of medical device experience from leadership roles at Insulet and ResMed. BVI has expanded its ophthalmic portfolio with FDA approvals for premium IOLs and new surgical platforms, positioning itself as a challenger i...
The global sleep tech devices market is expected to grow from USD 17 billion in 2024 to USD 44 billion by 2032, driven by rising sleep disorder prevalence, increased awareness, and technological advancements. Wearables dominate with 69.69% revenue share, while North America leads regional growth. Key players include Philips, ResMed, Apple, Garmin...
Nyxoah secured $77 million in financing through a private placement, registered direct offering, and convertible bond to support U.S. commercialization of its Genio system for treating Obstructive Sleep Apnea (OSA).
The Saudi Arabia Sleep Apnea Devices Market is projected to grow from $4.35 billion in 2024 to $5.94 billion by 2030, driven by increasing awareness of sleep disorders and demand for diagnostic and therapeutic technologies.
